Focuses on the decision of the Curie Institute in Paris, France to challenge the European patent obtained by Utah-based Myriad Genetics on the BRCA1 gene, used in tests to assess a patient's predisposition to hereditary breast and ovarian cancers. Grounds for challenging the patent including lack of novelty and inadequate description; Other European countries that may join the challenge.